Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

por Klempner, S.J., Janjigian, Y.Y., Wainberg, Z.A.
Publicado 2023

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

por Wainberg, Z A, Lin, L-S, DiCarlo, B, Dao, K M, Patel, R, Park, D J, Wang, H-J, Elashoff, R, Ryba, N, Hecht, J R
Publicado 2011

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

por Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., Ilankumaran, P., Burgess, P., Romero Salas, T., Keam, B.
Publicado 2022

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer

por Ankeny, J S, Court, C M, Hou, S, Li, Q, Song, M, Wu, D, Chen, J F, Lee, T, Lin, M, Sho, S, Rochefort, M M, Girgis, M D, Yao, J, Wainberg, Z A, Muthusamy, V R, Watson, R R, Donahue, T R, Hines, O J, Reber, H A, Graeber, T G, Tseng, H R, Tomlinson, J S
Publicado 2016